Albertsons Companies, Inc. - 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on April 14, 2026, by Albertsons Companies, Inc. The filing primarily addresses the announcement of financial results for the 13 and 53 weeks ended February 28, 2026, alongside significant corporate developments regarding litigation settlements and shareholder dividends.
Key Financial Metrics and Material Changes
- Opioid Settlement Charge: The Company recorded a pre-tax loss of approximately $774 million ($600 million net of tax) in the fourth quarter of fiscal 2025 related to an opioid settlement framework.
- Settlement Terms: The Company agreed to pay approximately $774 million over nine years. Slightly more than one-third is payable within the first two years, with the remainder over the following seven years.
- Net Present Value: The estimated after-tax net present value of the settlement payments is approximately $482 million.
- Adjusted Metrics: The settlement charge does not affect Adjusted EBITDA or Adjusted net income for fiscal 2025, as these non-GAAP measures exclude such charges.
- Dividend Increase: The Board of Directors increased the quarterly cash dividend by 13%, from $0.15 to $0.17 per common share.
Guidance, Outlook, and Contingencies
Opioid Settlement Framework: The settlement is subject to contingencies, including agreement by participating states, political subdivisions, and tribes during a sign-on period. The Company retains full discretion to determine if participation levels are sufficient for the framework to become effective. The first payment is expected on April 30, 2026, into escrow.
Legal Stance: The settlement does not constitute an admission of wrongdoing or liability. The Company will continue to vigorously defend against any litigation not covered by the framework.
Dividend Payment: The next quarterly dividend of $0.17 per share is scheduled for payment on May 8, 2026, to stockholders of record as of April 24, 2026.
Investor Verification Checklist
- Verify the final participation levels of states and tribes to confirm the Opioid Settlement Framework becomes effective.
- Review the full text of the press release (Exhibit 99.1) for detailed revenue, profit, and cash flow figures for the period ended February 28, 2026, as specific numbers are not detailed in this 8-K summary.
- Confirm the impact of the $774 million charge on the Company's liquidity and debt covenants, noting the payment schedule begins in April 2026.
- Monitor the Company's defense of any remaining opioid-related litigation not covered by the settlement framework.